- Summary:
- Dr. Reddy’s share price jumps as U.S. exempts pharma from global tariffs. Indian pharma stocks rally with bullish momentum across the sector.
As of April 3, 2025, Indian pharmaceutical stocks are gaining major traction, driven by the U.S. administration’s decision to exclude pharmaceutical products from new reciprocal global tariffs. The news has sparked bullish momentum across the entire Nifty Pharma index, with Dr Reddy’s Laboratories standing out as a top performer in Thursday’s session.
U.S. Tariff Relief Fuels Pharma Rally in India
The U.S. trade move to exempt pharma exports from its broad tariff overhaul brought immediate relief to India’s export-focused drug manufacturers.
Dr. Reddy’s share price jumped sharply at market open, supported by fresh buying interest and strong volume. The positive sentiment extended to peers like Cipla, Sun Pharma, Lupin, and Gland Pharma, all of which registered gains early in the session.
Dr. Reddy’s Technical Analysis
Current Price: ₹1,151.45
Resistance Levels: ₹1,173.30 – ₹1,215.50 – ₹1,252.85
Support Zones: ₹1,135.95 – ₹1,092.85 – ₹1,000.00
RSI : 45.88 – Neutral zone, slight bullish tilt
Momentum Outlook: Sideways to mildly bullish; upside needs confirmation above ₹1,173
Indian Pharma Stocks Outperform on Trade Policy Relief
The Nifty Pharma Index was the best-performing sector on April 3, rising over 2.5% intraday, with Dr. Reddy’s contributing significantly to the index’s strength. Other top movers included:
- Sun Pharma: Attempted to reclaim ₹1,800 levels
- Cipla: Found support near ₹1,500 and bounced
- Gland Pharma: Jumped over 8% on strong volumes
- Lupin and Divi’s Labs: Also participated in the sector-wide rebound
Outlook: Pharma in Focus as Trade Tensions Rise Elsewhere
While IT, auto, and FMCG stocks faced selling pressure due to broader trade war fears, pharma stood out as the clear defensive play. With tariffs now threatening multiple sectors, investors are rotating into pharmaceutical names as a relatively safe bet with consistent export revenue.
Dr. Reddy’s, backed by strong fundamentals and global exposure, could continue to lead the charge — provided the ₹1,135 support holds and the stock is able to reclaim momentum above ₹1,173.